ENDRA Life Sciences (NASDAQ:NDRA) Issues Quarterly Earnings Results, Misses Expectations By $0.18 EPS

ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) posted its earnings results on Monday. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.18), FiscalAI reports.

ENDRA Life Sciences Price Performance

Shares of ENDRA Life Sciences stock traded up $0.02 on Monday, hitting $4.43. 4,492 shares of the company’s stock traded hands, compared to its average volume of 51,423. ENDRA Life Sciences has a one year low of $2.96 and a one year high of $6.95. The company has a fifty day moving average of $5.32 and a two-hundred day moving average of $4.82. The company has a market capitalization of $6.64 million, a price-to-earnings ratio of -0.69 and a beta of -0.07.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of ENDRA Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, November 2nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, ENDRA Life Sciences currently has a consensus rating of “Hold” and an average price target of $25.00.

Get Our Latest Research Report on NDRA

About ENDRA Life Sciences

(Get Free Report)

ENDRA Life Sciences is a medical technology company developing imaging tools for the assessment of liver disease. Its technology is designed to provide clinicians with a non-invasive way to evaluate liver tissue and support the monitoring of conditions such as fatty liver disease. The company’s lead platform, TAEUS (Thermo-Acoustic Enhanced Ultrasound), combines radiofrequency energy with ultrasound to measure tissue characteristics, including liver fat. ENDRA is developing the system as an alternative or complement to existing approaches to liver assessment.

Read More

Earnings History for ENDRA Life Sciences (NASDAQ:NDRA)

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.